bioAffinity Technologies, Inc.
NASDAQTotal Valuation
bioAffinity Technologies, Inc. carries a market capitalization of 8.49M, placing it among publicly traded companies globally. Its enterprise value stands at -931,630.54, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.49M |
| Enterprise Value | -931,630.54 |
Share Statistics
bioAffinity Technologies, Inc. currently has 452,204.00 shares outstanding.
| Shares Outstanding | 452,204.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.02 |
| P/TBV Ratio | 0.04 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 0.06 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
bioAffinity Technologies, Inc. maintains a current ratio of 1.44, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 38.08, indicating elevated leverage, while an interest coverage ratio of -268.14 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.44 |
| Quick Ratio | 1.24 |
| Debt / Equity | 38.08 |
| Debt / EBITDA | -0.12 |
| Interest Coverage | -268.14 |
Financial Efficiency
| Return on Equity (ROE) | -1,169.65 |
| Return on Assets (ROA) | -245.51 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 61.08 |
Taxes
| Income Tax | 6,363.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
bioAffinity Technologies, Inc.'s stock has gained approximately 164.88889% over the past 52 weeks. The 50-day moving average sits at 0.20, while the 200-day moving average is 0.27.
| Beta (5Y) | N/A |
| 52-Week Price Change | 164.88889% |
| 50-Day Moving Average | 0.20 |
| 200-Day Moving Average | 0.27 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -12.02M, while operating income came in at -12.44M.
| Revenue | 5.85M |
| Gross Profit | 1.99M |
| Operating Income | -12.44M |
| Pretax Income | -15.18M |
| Net Income | -15.19M |
| EBITDA | -12.02M |
| EBIT | -12.44M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
bioAffinity Technologies, Inc. holds 2.43M in cash and equivalents against 1.44M in total debt, resulting in a net debt position of -2.37M. Total book value stands at 3.77M, with working capital of 1.18M providing operational flexibility.
| Cash & Cash Equivalents | 2.43M |
| Total Debt | 1.44M |
| Net Debt | -2.37M |
| Equity (Book Value) | 3.77M |
| Book Value Per Share | 8.33 |
| Working Capital | 1.18M |
Cash Flow
bioAffinity Technologies, Inc. produced -11.47M in operating cash flow over the past twelve months.
| Operating Cash Flow | -11.47M |
| Capital Expenditures | -91,988.00 |
| Free Cash Flow | -11.56M |
| FCF Per Share | N/A |
Margins
bioAffinity Technologies, Inc. operates with a gross margin of 34.00, reflecting its pricing power and cost economics. The operating margin of -212.68 and net profit margin of -259.71 provide insight into operational efficiency.
| Gross Margin | 34.00 |
| Operating Margin | -212.68 |
| Pretax Margin | -259.60 |
| Profit Margin | -259.71 |
| EBITDA Margin | -205.62 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -20,904.51 |
| FCF Yield | N/A |
Scores
bioAffinity Technologies, Inc. posts an Altman Z-Score of -25.24, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -25.24 |